SCHEMBL31067445

SCHEMBL31067445

Nc1cc(C(O)c2ccccn2)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.39
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
MAPT P10636 1/20 0.38
BRD4 O60885 1/20 0.38
KCNH2 Q12809 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
KDM4E B2RXH2 2/20 0.36
SLC10A1 Q14973 1/20 0.35
RECQL P46063 1/20 0.35
ADRA2A P08913 2/20 0.35
CYP2C9 P11712 2/20 0.35
TSHR P16473 2/20 0.35
ADRA1A P35348 2/20 0.35
OPRK1 P41145 2/20 0.35
ABCB11 O95342 1/20 0.35
LMNA P02545 1/20 0.35
ESR1 P03372 1/20 0.35
PDE4A P27815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17064435 1.00 SLC6A3 (0.39) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL133373 0.80 SLC6A2 (0.46) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL7677713 0.79 SLC6A3 (0.39) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL17064838 0.78 SLC6A2 (0.47) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL31067503 0.78 SLC6A2 (0.47) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL23610045 0.77 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL17064619 0.77 CA1 (0.41) SLC6A3SLC6A2SLC6A4KCNH2CYP3A4
SCHEMBL5655372 0.77 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL5655181 0.77 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4MAPTBRD4
SCHEMBL17842469 0.77 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4MAPTBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 CN disclosed